Ranitidin ratiopharm 150 mg Norge - norsk - Statens legemiddelverk

ranitidin ratiopharm 150 mg

ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 150 mg

Ranitidin ratiopharm 300 mg Norge - norsk - Statens legemiddelverk

ranitidin ratiopharm 300 mg

ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 300 mg

Zantac 150 mg Norge - norsk - Statens legemiddelverk

zantac 150 mg

glaxosmithkline as - ranitidinhydroklorid - brusetablett - 150 mg

Zantac 25 mg/ ml Norge - norsk - Statens legemiddelverk

zantac 25 mg/ ml

glaxosmithkline as - ranitidinhydroklorid - injeksjonsvæske, oppløsning - 25 mg/ ml

Zantac 150 mg Norge - norsk - Statens legemiddelverk

zantac 150 mg

glaxosmithkline as - ranitidinhydroklorid - tablett - 150 mg

Ranitidin ratiopharm 75 mg Norge - norsk - Statens legemiddelverk

ranitidin ratiopharm 75 mg

ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 75 mg

Enalapril Comp ratiopharm 20 mg / 12.5 mg Norge - norsk - Statens legemiddelverk

enalapril comp ratiopharm 20 mg / 12.5 mg

ratiopharm gmbh - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 12.5 mg

Zestoretic 20 mg / 12.5 mg Norge - norsk - Statens legemiddelverk

zestoretic 20 mg / 12.5 mg

atnahs pharma netherlands b.v. - lisinoprildihydrat / hydroklortiazid - tablett - 20 mg / 12.5 mg

Axura Den europeiske union - norsk - EMA (European Medicines Agency)

axura

merz pharmaceuticals gmbh - memantinhydroklorid - alzheimers sykdom - andre anti-demens medisiner - behandling av pasienter med moderat til alvorlig alzheimers sykdom.

BiResp Spiromax Den europeiske union - norsk - EMA (European Medicines Agency)

biresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).